Organising housing and service provision for persons with co-occurring substance use and mental health problems: a scoping review in the ROP Municipal - Top-Institutions - MDSpire

Organising housing and service provision for persons with co-occurring substance use and mental health problems: a scoping review in the ROP Municipal

  • By

  • Minna Sorsa

  • Unn Hammervold

  • Silje Lill Rimstad

  • Marianne Storm

  • Hildegunn Sagvaag

  • December 11, 2025

  • 0 min

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Psychiatry
    • Addiction Medicine
    • Public Health

  • #2

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Psychiatry
    • Addiction Medicine
    • Social Work

  • #3

    Columbia University Irving Medical Center
    Columbia University Irving Medical Center

    New York, NY

    Key Differentiators

    • Psychiatry
    • Addiction Medicine
    • Public Health

  • #4

    University of Toronto
    University of Toronto

    Toronto, ON

    Key Differentiators

    • Psychiatry
    • Addiction Medicine
    • Social Work

  • #5

    King’s College London
    King’s College London

    London, England

    Key Differentiators

    • Psychiatry
    • Addiction Medicine
    • Public Health

Original Source(s)

Organising housing and service provision for persons with co-occurring substance use and mental health problems: a scoping review in the ROP Municipal

  • by Minna Sorsa, Unn Hammervold, Silje Lill Rimstad, Marianne Storm, Hildegunn Sagvaag

  • December 11, 2025

Related Content

Fentanyl Is Not a WMD

Artificial Intelligence Centrality in Psychotic Delusions and Violence Risk in Forensic Psychiatry: Retrospective Observational Study of Judicial Decisions

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.